By Associate Professor Yeh Chen Lee

Journal articles

Haggstrom L; Lee YC; Scott C; Harter P; Woelber L; Ledermann J; Gourley C; McNeish IA; Amant F; Ray-Coquard I; Leary A; Oza AM; Tinker A; González Martin A; Cecere SC; Pignata S; Colombo N; Yoshida H; Marth C; Rosengarten O; Moore KN; Gómez-García EM; Tan D; Friedlander ML, 2024, 'How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.', Int J Gynecol Cancer, 34, pp. 1932 - 1939, http://dx.doi.org/10.1136/ijgc-2024-005976

Lefkovits YR; Heriot N; Sporik A; Perera S; Friedlander M; Dixon C; Cohen PA; Lee YC; Hyde S; Richardson G; Webb P; Rome R; King M; Zalcberg J; Schofield P, 2024, 'Incorporating patient-reported outcome measures (PROMs) into a clinical quality registry (CQR) for ovarian cancer: considerations and challenges', BMC Health Services Research, 24, http://dx.doi.org/10.1186/s12913-024-11042-8

Werner B; Powell E; Duggan J; Cortesi M; Lee YC; Arora V; Athavale R; Dean M; Warton K; Ford CE, 2024, 'Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer', Molecular Oncology, 18, pp. 2668 - 2683, http://dx.doi.org/10.1002/1878-0261.13710

Colombo N; Biagioli E; Harano K; Galli F; Hudson E; Antill Y; Choi CH; Rabaglio M; Marmé F; Marth C; Parma G; Fariñas-Madrid L; Nishio S; Allan K; Lee YC; Piovano E; Pardo B; Nakagawa S; McQueen J; Zamagni C; Manso L; Takehara K; Tasca G; Ferrero A; Tognon G; Lissoni AA; Petrella M; Laudani ME; Rulli E; Uggeri S; Barretina Ginesta MP; Zola P; Casanova C; Arcangeli V; Antonuzzo L; Gadducci A; Cosio S; Clamp A; Persic M; McNeish I; Tookman L; Redondo Sanchez A; Baldini E; Palaia I; Benedetti Panici P; Takahashi N; Lombard J; Ardizzoia A; Bologna A; Herrero Ibáñez AM; Musolino A; Márquez Vázquez R; Pietzner K; Braicu E; Heinzelmann-Schwarz VA; Powell M; Yokoyama Y; Baron-Hay S; Abeni C; Martin Lorente C; Cueva JF; Trillsch F; Heitz F; Ataseven B; Petru E; Heubner ML; Sadozye AH; Dubey S; Tazbirkova A; Tiley S; Chrystal K; Kim SW; Fehr M; Scatchard K; Anand A; Taylor A; Watary H; Enomoto T; Yoshihara K; Selva-Nayagam S; Karki B; Harrison M; Wilkinson K; Goh J; Glasgow A; Chantrill L; Lee C; Bertolini A; Narducci F; Bellotti G; Fusco V; Aebi S; Del Grande M; Colombo I; Tokunaga H; Shigeta S; Goss G; Siow ZR; Steer C; Lin H, 2024, 'Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, 25, pp. 1135 - 1146, http://dx.doi.org/10.1016/S1470-2045(24)00334-6

Rajadevan N; Flinkier A; Saunders H; Lee YC; Scott C; Khaw P; Allan P; Davies C; Andrews J; Wilson M; Lombard JM; Harrison M; Nesfield H; DeFazio A; Meniawy T; Gorringe KL, 2024, 'Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand', Australian and New Zealand Journal of Obstetrics and Gynaecology, 64, pp. 319 - 325, http://dx.doi.org/10.1111/ajo.13792

Van Nieuwenhuysen E; Bouberhan S; Papadimitriou K; Arend RC; Lee J-Y; O'Cearbhaill RE; O'Malley DM; You B; Gonzalez Martin A; Michels J; Mileshkin LR; Lee YC; Miller R; Yoo S-Y; Peterman MJ; Schmidt T; Knorr D; Lowy I; Uldrick TS; Miller E, 2024, 'A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.', Journal of Clinical Oncology, 42, pp. TPS5632 - TPS5632, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.tps5632

Oaknin A; Lee J-Y; Cibula D; Lee YC; Schilder RJ; Auranen A; Gao B; Tan DSP; Oza AM; Miller R; Salutari V; Tasca G; O'Malley DM; Monk BJ; Pothuri B; Lu L; Berman C; Borgman A; Naumann RW, 2024, 'Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.', Journal of Clinical Oncology, 42, pp. TPS5637 - TPS5637, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.tps5637

Roncolato F; King MT; O'Connell RL; Lee YC; Joly F; Hilpert F; Lanceley A; Yoshida Y; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Kaminsky MC; Stockler MR; Friedlander M, 2024, 'Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer', Gynecologic Oncology, 185, pp. 128 - 137, http://dx.doi.org/10.1016/j.ygyno.2024.02.025

Naidoo M; Scott CL; McNally O; Rome R; Perera S; Lee YC; Whitely A; Burling M; Anderson L; Cohen P; Richardson GE; Friedlander M; Brand A; Hyde S; Bunting M; Jobling T; Zalcberg JR, 2024, 'Overall survival and patterns of care for women with rare ovarian cancers: A prospective study from the Australian National Gynae-Oncology Registry (NGOR).', Journal of Clinical Oncology, 42, pp. e17554 - e17554, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e17554

Lee YC; Castellano T; Myers TKN; Barnes EH; Chase DM; McCormick C; Diamante K; Shannon CM; Huh WK; Lea JS; Walker JL; Small W; Miller K; Govindarajulu G; Monk BJ; Stockler MR; Moore KN; Mileshkin LR; Bae-Jump VL, 2024, 'Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).', Journal of Clinical Oncology, 42, pp. 1594 - 1594, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.1594

Garg V; Alqaisi H; Soberanis Pina P; Veneziani A; Pannu AK; Grant B; Braik D; Wang C; Shukla A; Tesfu A; Odujoko O; Madariaga A; Lee YC; Wang L; Jivraj N; Bowering V; Grant RC; Dhani NC; Oza AM; Lheureux S, 2024, 'Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in women with advanced gynaecological cancers: A prospective study.', Journal of Clinical Oncology, 42, pp. 12076 - 12076, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.12076

Werner B; Powell E; Duggan J; Cortesi M; Lee YC; Arora V; Athavale R; Dean M; Warton K; Ford C, 2024, 'Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer.', Journal of Clinical Oncology, 42, pp. 5547 - 5547, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5547

Symons R; Heath F; Duggan J; Bui KT; Byun L; Friedlander M; Lee YC, 2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol as primary prophylaxis.', Support Care Cancer, 32, pp. 292, http://dx.doi.org/10.1007/s00520-024-08460-z

Grisham R; Monk BJ; Van Nieuwenhuysen E; Moore KN; Fabbro M; O'Malley DM; Oaknin A; Thaker P; Oza AM; Colombo N; Gershenson D; Aghajanian CA; Choi CH; Lee YC; Mirza MR; Coleman RL; Cobb L; Harter P; Lustgarten S; Youssoufian H; Banerjee S, 2024, 'GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer', International Journal of Gynecological Cancer, http://dx.doi.org/10.1136/ijgc-2024-005919

Giani C; Salawu A; Ljevar S; Denu RA; Napolitano A; Palmerini E; Connolly EA; Ogura K; Wong DD; Scanferla R; Rosenbaum E; Bajpai J; Li ZCC; Bae S; D'Ambrosio L; Bialick S; Wagner AJ; Lee ATJ; Koseła-Paterczyk H; Baldi GG; Brunello A; Lee YC; Loong HH; Boikos S; Campos F; Cicala CM; Maki RG; Hindi N; Figura C; Almohsen SS; Patel S; Jones RL; Ibrahim T; Karim R; Kawai A; Carey-Smith R; Boyle R; Taverna SM; Lazar AJ; Demicco EG; Bovee JVMG; Dei Tos AP; Fletcher C; Baumhoer D; Sbaraglia M; Schaefer IM; Miceli R; Gronchi A; Stacchiotti S, 2024, 'International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease', American Journal of Surgical Pathology, http://dx.doi.org/10.1097/PAS.0000000000002330

Scott CL; Friedlander ML; Francis K; Kartikasari AER; Diamante K; Bound N; Davies C; O’Connell R; Lee YC; Lombard J; Baron-Hay SE; Antill Y; Shannon C; Selva-Nayagam S; Beale PJ; Shield-Artin K; Wakefield M; Vandenberg C; Plebanski M; Lee CK, 2024, '747P SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC)', Annals of Oncology, 35, pp. S566 - S567, http://dx.doi.org/10.1016/j.annonc.2024.08.808

Haggstrom LR; Lee YC; Scott CL; Ledermann JA; Gourley C; McNeish I; Amant F; Ray-Coquard IL; Leary A; Oza AM; Tinker A; González-Martín A; Cecere SC; Colombo N; Yoshida H; Marth C; Gomez Garcia EM; Tan DS; Moore KN; Friedlander ML, 2024, '764P How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in platinum sensitive recurrent ovarian cancer and long-term outcomes', Annals of Oncology, 35, pp. S578 - S579, http://dx.doi.org/10.1016/j.annonc.2024.08.825

Nicum S; Ledermann JA; Mileshkin L; Jayson GC; Gourley C; Michael A; Lord R; Mackay H; Hall M; Tookman L; Banerjee S; Harnett P; Macdonald I; Lee YC; Elyashiv O; Wilkinson K; Farrelly L; Counsell N, 2024, 'LBA33 ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy', Annals of Oncology, 35, pp. S1225 - S1226, http://dx.doi.org/10.1016/j.annonc.2024.08.2272

Gonzalez-Ochoa E; Milosevic M; Corr B; Abbruzzese JL; Girda E; Miller RW; Croke J; Mackay H; Lee YC; Bowering V; Ramsahai J; Wang L; D'Souza A; Kunos CA; Oza AM; Lheureux S, 2023, 'A phase i study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers', International Journal of Gynecological Cancer, 33, pp. 1208 - 1214, http://dx.doi.org/10.1136/ijgc-2023-004491

Mileshkin LR; Narayan K; Gaffney DK; Barnes EH; Lee YC; Monk BJ; Stockler MR, 2023, 'Adjuvant chemotherapy for locally advanced cervical cancer – Authors’ reply', The Lancet Oncology, 24, pp. e290, http://dx.doi.org/10.1016/S1470-2045(23)00294-2

Lindemann K; Liland H; Donner MS; Brew S; Lee YC; Vistad I; Berge Nilsen E; Lombard JM; Mirza MR; Madsen K; Hansson AM; Andrews J; Campbell R; Davis AJ, 2023, 'GCIG SB-001/NSGO-CTU-PEACE/ANZGOG 1923/2020: Palliation in gynae-oncology—Patients' expectations and assessment of care.', Journal of Clinical Oncology, 41, pp. TPS5635 - TPS5635, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps5635

Buchanan DD; Mahmood K; Georgeson P; Walker R; Robledo K; Cummins MM; Spurdle AB; Smith DS; Joo E; Clendenning M; Como J; Preston S; Yip S; Andrews J; Kok PS; Lee YC; Stockler MR; Mileshkin LR; Antill YC, 2023, 'The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601).', Journal of Clinical Oncology, 41, pp. 5604 - 5604, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5604

Mileshkin LR; Moore KN; Barnes EH; Gebski V; Narayan K; King MT; Bradshaw N; Lee YC; Diamante K; Fyles AW; Small W; Gaffney DK; Khaw P; Brooks S; Thompson JS; Huh WK; Mathews CA; Buck M; Suder A; Lad TE; Barani IJ; Holschneider CH; Van Dyk S; Quinn M; Rischin D; Monk BJ; Stockler MR, 2023, 'Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial', The Lancet Oncology, 24, pp. 468 - 482, http://dx.doi.org/10.1016/S1470-2045(23)00147-X

Pitiyarachchi O; Lee YC; Sim HW; Srirangan S; Mapagu C; Kirk J; Harnett PR; Balleine RL; Bowtell DDL; Samimi G; Brand AH; Marsh DJ; Beale P; Anderson L; Bouantoun N; Provan P; Ramus SJ; DeFazio A; Friedlander M, 2023, 'Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma', Translational Oncology, 31, http://dx.doi.org/10.1016/j.tranon.2023.101638

Hayes S; Obermair A; Mileshkin L; Davis A; Gordon LG; Eakin E; Janda M; Beesley VL; Barnes EH; Spence RR; Sandler C; Jones T; Vagenas D; Webb P; Andrews J; Brand A; Lee YC; Friedlander M; Pumpa K; O'Neille H; Williams M; Stockler M, 2023, 'Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: Design and implementation of a randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2022-067925

Klingberg D; Bae S; Zhou DDX; Sim HW; Cai R; Anazodo A; Grimison P; Lewis C; Lee YC, 2023, 'Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma', Asia-Pacific Journal of Clinical Oncology, http://dx.doi.org/10.1111/ajco.13998

Cohen PA; Webb PM; King M; Obermair A; Gebski V; Butow P; Morton R; Lawson W; Yates P; Campbell R; Meniawy T; McMullen M; Dean A; Goh J; McNally O; Mileshkin L; Beale P; Beach R; Hill J; Dixon C; Hegarty S; Codde J; Ives A; Lee YC; Brand A; Mellon A; Bilic S; Black I; Jeffares S; Friedlander M, 2023, 'Getting the MOST out of follow-up: A randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer', International Journal of Gynecological Cancer, http://dx.doi.org/10.1136/ijgc-2021-002999

Jivraj N; Lee YC; Tinker L; Bowering V; Ferguson SE; Croke J; Karakasis K; Chawla T; Lau J; Ng P; Dhar P; Shlomovitz E; Buchanan S; Dhani N; Oza AM; Stuart-Mcewan T; Lheureux S, 2023, 'Management of Malignant Bowel Obstruction: An Innovative Proactive Outpatient Nurse-Led Model of Care for Patients With Advanced Gynecologic Cancer', Journal of Nursing Care Quality, 38, pp. 69 - 75, http://dx.doi.org/10.1097/NCQ.0000000000000661

Smith D; Robledo KP; Yip S; Cummins MM; Kok PS; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Spurdle AB; Andrews J; Stockler MR; Mileshkin L; Antill Y, 2023, 'Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)', Cancers, 15, http://dx.doi.org/10.3390/cancers15010254

Friedlander M; Lee YC; Tew WP, 2023, 'Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data.', Am Soc Clin Oncol Educ Book, 43, pp. e390876, http://dx.doi.org/10.1200/EDBK_390876

Campbell R; King MT; Stockler MR; Lee YC; Roncolato FT; Friedlander ML, 2023, 'Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice.', Patient Relat Outcome Meas, 14, pp. 111 - 126, http://dx.doi.org/10.2147/PROM.S297301

Woopen H; Sehouli J; Davis A; Lee YC; Cohen PA; Ferrero A; Gleeson N; Jhingran A; Kajimoto Y; Mayadev J; Barretina-Ginesta MP; Sundar S; Suzuki N; van Dorst E; Joly F, 2022, 'Erratum to “GCIG-Consensus guideline for long-term survivorship in gynecologic cancer: A position paper from the Gynecologic Cancer InterGroup (GCIG) symptom benefit committee” [Cancer Treatm. Rev. 107 (2022) 102396] (Cancer Treatment Reviews (2022) 107, (S0305737222000603), (10.1016/j.ctrv.2022.102396))', Cancer Treatment Reviews, 109, http://dx.doi.org/10.1016/j.ctrv.2022.102431

Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky MC; Diamante K; Stockler MR; Friedlander ML, 2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical and Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/OGX.0000000000001075

Campbell R; Costa DSJ; Stockler MR; Lee YC; Ledermann JA; Berton D; Sehouli J; Roncolato FT; Connell RO; Okamoto A; Bryce J; Oza AM; Avall-Lundqvist E; Berek JS; Lanceley A; Joly F; Hilpert F; Feeney A; Kaminsky MC; Diamante K; Friedlander ML; King MT, 2022, 'Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer', Gynecologic Oncology, 166, pp. 254 - 262, http://dx.doi.org/10.1016/j.ygyno.2022.05.024

Sivakumaran T; Krasovitsky M; Freimund A; Lee YC; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G, 2022, 'Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients', International Journal of Gynecological Cancer, 32, pp. 906 - 912, http://dx.doi.org/10.1136/ijgc-2021-003009

Delahunty R; Nguyen L; Craig S; Creighton B; Ariyaratne D; Garsed DW; Christie E; Fereday S; Andrews L; Lewis A; Limb S; Pandey A; Hendley J; Traficante N; Carvajal N; Spurdle AB; Thompson B; Parsons MT; Beshay V; Volcheck M; Semple T; Lupat R; Doig K; Yu J; Chen XQ; Marsh A; Love C; Bilic S; Beilin M; Nichols CB; Greer C; Lee YC; Gerty S; Gill L; Newton E; Howard J; Williams R; Norris C; Stephens AN; Tutty E; Smyth C; O'connell S; Jobling T; Stewart CJR; Tan A; Fox SB; Pachter N; Li J; Ellul J; Mir Arnau G; Young MA; Gordon L; Forrest L; Harris M; Livingstone K; Hill J; Chenevix-Trench G; Cohen PA; Webb PM; Friedlander M; James P; Bowtell D; Alsop K, 2022, 'TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members', Journal of Clinical Oncology, 40, pp. 2036 - 2047, http://dx.doi.org/10.1200/JCO.21.02108

Woopen H; Sehouli J; Davis A; Lee YC; Cohen PA; Ferrero A; Gleeson N; Jhingran A; Kajimoto Y; Mayadev J; Barretina-Ginesta MP; Sundar S; Suzuki N; van Dorst E; Joly F, 2022, 'GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee', Cancer Treatment Reviews, 107, http://dx.doi.org/10.1016/j.ctrv.2022.102396

Krasovitsky M; Lee YC; Sim HW; Chawla T; Moore H; Moses D; Baker L; Mandel C; Kielar A; Hartery A; O'Malley M; Friedlander M; Oza AM; Wang L; Lheureux S; Wilson M, 2022, 'Interobserver and intraobserver variability of RECIST assessment in ovarian cancer', International Journal of Gynecological Cancer, 32, pp. 656 - 661, http://dx.doi.org/10.1136/ijgc-2021-003319

Farrell R; Burling M; Lee YC; Pather S; Robledo K; Mercieca-Bebber R; Stockler M, 2022, 'Clinical trial protocol for HyNOVA: Hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage iii epithelial ovarian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020)', Journal of Gynecologic Oncology, 33, http://dx.doi.org/10.3802/JGO.2022.33.E1

Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky M-C; Diamante K; Stockler MR; Friedlander ML, 2022, 'Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study', Obstetrical & Gynecological Survey, 77, pp. 531 - 533, http://dx.doi.org/10.1097/ogx.0000000000001075

Obermair A; Beale P; Scott CL; Beshay V; Kichenadasse G; Simcock B; Nicklin J; Lee YC; Cohen P; Meniawy T, 2021, 'Insights into ovarian cancer care: Report from the Anzgog ovarian cancer webinar series 2020', Journal of Gynecologic Oncology, 32, http://dx.doi.org/10.3802/JGO.2021.32.E95

Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C, 2021, 'Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer', Gynecologic Oncology, 162, pp. 720 - 727, http://dx.doi.org/10.1016/j.ygyno.2021.06.028

Mileshkin LR; Moore KN; Barnes E; Gebski V; Narayan K; Bradshaw N; Lee YC; Diamante K; Fyles AW; Small W; Gaffney DK; Khaw P; Brooks S; Thompson JS; Huh WK; Carlson M; Mathews CA; Rischin D; Stockler MR; Monk BJ, 2021, 'Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).', Journal of Clinical Oncology, 39, pp. LBA3 - LBA3, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.lba3

Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L, 2021, 'Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial', Journal for ImmunoTherapy of Cancer, 9, http://dx.doi.org/10.1136/jitc-2020-002255

Madariaga A; Garg S; Bruce JP; Thiryayi S; Mandilaras V; Rath P; Oza AM; Dhani NC; Cescon DW; Lee YC; Chen E; Wang L; Clarke B; Lheureux S, 2020, 'Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer', Gynecologic Oncology, 159, pp. 539 - 545, http://dx.doi.org/10.1016/j.ygyno.2020.08.032

Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM, 2020, 'EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib plus Olaparib for Ovarian Cancer after PARP Inhibition Progression', Clinical Cancer Research, 26, pp. 4206 - 4215, http://dx.doi.org/10.1158/1078-0432.CCR-19-4121

Cusimano MC; Sajewycz K; Nelson M; Jivraj N; Lee YC; Bowering V; Oza A; Lheureux S; Ferguson SE, 2020, 'Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study', Gynecologic Oncology, 157, pp. 745 - 753, http://dx.doi.org/10.1016/j.ygyno.2020.03.009

Liu SL; Lee YC; Jivraj N; Bowering V; Wang L; Bhat G; Madariaga A; Kasherman L; Nathwani K; Tesfu A; Lee S; Ferguson SE; Croke JM; O'Brien C; Lau J; Chawla T; Schlomovitz E; Oza AM; Lheureux S, 2020, 'Risk stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with gynecological cancers: Preliminary results from a prospective single-center study.', Journal of Clinical Oncology, 38, pp. 6062 - 6062, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6062

Lee YC; Wang L; Kohn EC; Rubinstein L; Ivy SP; Harris PJ; Lheureux S, 2020, 'Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer', Cancer, 126, pp. 2139 - 2145, http://dx.doi.org/10.1002/cncr.32783

Madariaga A; Garg S; Bruce J; Rath P; Mandilaras V; Thiryayi S; Oza AM; Dhani N; Lee YC; Clarke BA; Lheureux S, 2020, 'Biomarkers of outcome with weekly paclitaxel in platinum-resistant high-grade serous or endometrioid ovarian carcinoma', Gynecologic Oncology, 159, pp. 149 - 149, http://dx.doi.org/10.1016/j.ygyno.2020.05.207

Back to profile page